Johnson Y.N. Lau

Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in U.S. history. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals and also as the Senior Director of Antiviral Therapy at Schering-Plough. Johnson has contributed more than 250 scientific publications and editorials / reviews / chapters in peer-reviewed scientific journals and has edited two books. He was a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee and the Corporate Governance Committee in addition to a number of other public and privately-owned companies. Johnson is currently serving on the Board of various private companies including Avalon Biomedical Management Limited, Aiviva Corporation, C-MER D&J Technology Limited, RainsOptics Limited, and Hong Kong X-tech Startup platform (general partner and mentor). He is an honorary professor/adjunct professor of the Hong Kong Polytechnic University. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong and is a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid-2011.